Fernandez-Fairen M.,Institute Cirugia Ortopedica Y Traumatologia Of Barcelona |
Hernandez-Vaquero D.,Hospital de San Agustin |
Murcia A.,Hospital de Cabuenes |
Torres A.,Hospital Universitario Santa Lucia |
Llopis R.,Hospital Universitario Santa Cristina
Clinical Orthopaedics and Related Research | Year: 2013
Background: Porous tantalum is an option of cementless fixation for TKA, but there is no randomized comparison with a cemented implant in a mid-term followup. Questions/purposes: We asked whether a tibial component fixed by a porous tantalum system might achieve (1) better clinical outcome as reflected by the Knee Society Score (KSS) and WOMAC Osteoarthritis Index, (2) fewer complications and reoperations, and (3) improved radiographic results with respect to aseptic loosening compared with a conventional cemented implant. Methods: We randomized 145 patients into two groups, either a porous tantalum cementless tibial component group (Group 1) or cemented conventional tibial component in posterior cruciate retaining TKA group (Group 2). Patients were evaluated preoperatively and 15 days, 6 months, and 5 years after surgery, using the KSS and the WOMAC index. Complications, reoperations, and radiographic failures were tallied. Results: At 5-year followup the KSS mean was 90.4 (range, 68-100; 95% CI, ± 1.6) for Group 1, and 86.5 (range, 56-99; 95% CI, ± 2.4) for Group 2. The effect size, at 95% CI for the difference between means, was 3.88 ± 2.87. The WOMAC mean was 15.1 (range, 0-51; 95% CI, ± 2.6) for the Group 1, and 19.1 (range, 4-61; 95% CI, ± 2.9) for Group 2. The effect size for WOMAC was -4.0 ± 3.9. There were no differences in the frequency of complications or in aseptic loosening between the two groups. Conclusions: Our data suggest there are small differences between the uncemented porous tantalum tibial component and the conventional cemented tibial component. It currently is undetermined whether the differences outweigh the cost of the implant and the results of their long-term performance. Level of Evidence: Level I, therapeutic study. See Instructions to Authors for a complete description of levels of evidence. © 2013 The Association of Bone and Joint Surgeons®.
Ruiz-Roso B.,Complutense University of Madrid |
Quintela J.C.,Puleva Biotech S.A. |
de la Fuente E.,Puleva Biotech S.A. |
Haya J.,Hospital Universitario Santa Cristina |
Perez-Olleros L.,Complutense University of Madrid
Plant Foods for Human Nutrition | Year: 2010
Recently, polyphenols have been found to affect blood lipids in animals in a similar manner as soluble dietary fibre. The aim was to assess whether an insoluble dietary fiber very rich in polyphenols has a beneficial effect on serum lipids in humans. In a double-blind randomized placebo-controlled clinical study with parallel arms, 88 volunteers with hypercholesterolemia were randomly assigned to consume daily either, fiber with insoluble 84% polyphenols 4 g twice a day (n=43) or placebo (n=45). Serum total, LDL and HDL cholesterol and triglycerides were assessed at baseline and after 4 weeks. The insoluble polyphenols consumption reduced the total cholesterol by 17.8 ± 6.1% (p<0.05), LDL cholesterol by 22.5 ± 8.9% (p <0.001), LDL: HDL cholesterol ratio by 26.2± 14.3% (p<0.001) and triglycerides by 16.3 ± 23.4% (p<0.05) at the end of the study compared with baseline. No significant differences were found during the study time in the placebo group for the lipid profile. The consumption of fiber very rich in insoluble polyphenols shows beneficial effects on human blood lipid profile and may be effective in prevention and treatment of hyperlipemia. © Springer Science+Business Media, LLC 2010.
Alpha blockers: Effects on improvement of erectile dysfunction and sexual desire in patients with benign prostatic hypertrophy [Alfabloqueantes: Efectos en la mejora de la disfunción eréctil y el deseo sexual en pacientes con hipertrofia prostática benigna]
Balmori C.,Hospital Universitario Santa Cristina
Revista Internacional de Andrologia | Year: 2013
Objectives: To assess the impact of benign prostatic hyperplasia on both quality of life and sexual function as well as the benefits of using alpha-blockers, especially silodosin. Material and method: Epidemiological observational, multicenter nationwide study in which the data collection was performed retrospectively. A total of 175 urologists, who recruited 900 patients, participated in the study. Descriptive statistics of all variables were carried out, including measures of central tendency, dispersion for quantitative variables, and absolute and relative frequencies for qualitative variables. Results: At the beginning of treatment, 31.6% of the patients reported a lack of desire. This proportion decreased to 26.6% at the end of the study (P< .0001). When the treatment was initiated, 64.6% of patients had mild or absent erectile dysfunction. This has increased to 71% at the present time (P= .0002). Conclusions: Adequate selection of patients who may benefit from treatment with alpha-blocker, explanation of their benefits and side effects will not only improved lower urinary tract symptoms, but also erectile dysfunction scores. In this case, the most uroselective alpha-blocker silodosin has shown excellent results in both fields, both when administered as monotherapy or associated with PDE5 inhibitors. Furthermore, use of silodosin improved sexual desire parameter as opposed to use of 5 alpha reductase inhibitors. © 2013 Asociación Española de Andrología, Medicina Sexual y Reproductiva.
Cabo J.,Hospital Universitario Santa Cristina |
Alonso R.,IIS Fundacion Jimenez Diaz |
Mata P.,IIS Fundacion Jimenez Diaz
British Journal of Nutrition | Year: 2012
Epidemiological and clinical studies suggest that consumption of omega (w-3) polyunsaturated fatty acids (PUFA) contributes to the reduction of cardiovascular mortality through different mechanisms including modulation of cellular metabolic functions, gene expression and beneficial effects on lipid profile or blood pressure. The aim of the study is to review the effects of w-3 PUFA supplemented as fish oil or blue fish in blood pressure. The analysis of different studies suggests that high doses w-3 PUFA ( ≥ 3 g/day) produces a small but significant decrease in blood pressure, especially systolic blood pressure, in older and hypertensive subjects; however, the evidence is not consistent among different studies. w-3 polyunsaturated fatty acids consumption might have a place in the control of patients with mild hypertension before starting drug treatment and of those who prefer changes of lifestyles like diet. © 2012 The Authors.
Vigano R.,Ferrari |
Marega L.,Casi di Cura S. Anna |
Breemans E.,Gelre Ziekenhuizen Apeldoorn |
Miro R.L.,Hospital Universitario Santa Cristina
Acta Orthopaedica Belgica | Year: 2012
Despite more than a decade of use, there are currently no comprehensive reviews summarising clinical results with the Profix Total Knee System in primary total knee arthroplasty. Searching the PubMed and Google Scholar databases revealed 17 potentially relevant Profix manuscripts. After author review and exclusion of studies not meeting predetermined variables, 8 manuscripts were selected. Knee Society data were provided in all 8 and implant survival data in 4. Data for 987 patients (1152 knees) were available. The overall estimated implant survival was 98.6% at 5 years and 94.2% at 10 years with revision for any reason as an endpoint, and 100% at both time points with radiographic loosening as an endpoint. Mean/median preoperative Knee Society knee scores improved from 39.2/24.7 at baseline, to 91.4/92.1 at the last postoperative follow-up visit. Good mediumto long-term clinical results can be expected with the Profix in primary total knee arthroplasty. © 2012, Acta Orthopædica Belgica.